About

ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role. Our current focus is on cardiovascular disorders and inflammatory disorders with a large unmet medical need.
The company’s assets and discoveries are based on work performed by Professor Mauro Perretti and his team at the Queen Mary University in London, UK. Professor Perretti is a pioneer in the area resolution therapy and has spent decades pinpointing the role of Annexin 1A and its receptors in the resolution of chronic inflammation.